Anixa Biosciences, Inc. (ANIX) Stock Forecast
ANIX analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 4 analysts
- Price target
- $9.75 average of analyst targets
- Upside to target
- +265.2% from the latest close
- Next earnings
- —
- 52-week range
- $2.35 – $5.22
ANIX analyst ratings
4 analystsNumber of analysts at each rating.
ANIX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ANIX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Jul '26) | −$0.08 | −$0.08 | −$0.08 | −$0.07 | −14.3% | 1 |
| Next quarter (Jan '27) | −$0.08 | −$0.08 | −$0.08 | −$0.08 | 0.0% | 1 |
| Current fiscal year (FY2026) | −$0.31 | −$0.31 | −$0.31 | −$0.34 | +8.8% | 1 |
| Next fiscal year (FY2027) | −$0.31 | −$0.31 | −$0.31 | −$0.31 | 0.0% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ANIX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Jul '26) | $0 | $0 | $0 | 0.0% | 4 |
| Next quarter (Jan '27) | $0 | $0 | $0 | 0.0% | 3 |
| Current fiscal year (FY2026) | $0 | $0 | $0 | 0.0% | 4 |
| Next fiscal year (FY2027) | $0 | $0 | $0 | 0.0% | 4 |
ANIX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ANIX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Jul '26) | −$0.09 | −$0.09 | −$0.09 | −$0.09 | −$0.08 | −11.1% | 1 up · 0 down |
| Next quarter (Jan '27) | −$0.08 | −$0.08 | −$0.08 | −$0.08 | −$0.08 | 0.0% | 0 up · 0 down |
| Current fiscal year (FY2026) | −$0.31 | −$0.31 | −$0.31 | −$0.31 | −$0.31 | 0.0% | 1 up · 0 down |
| Next fiscal year (FY2027) | −$0.31 | −$0.31 | −$0.31 | −$0.31 | −$0.31 | 0.0% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ANIX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ANIX beat in 11 of 12.
What analysts expect from ANIX
4 analysts cover Anixa Biosciences; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $9.75, 265.2% above the latest close of $2.67. Analysts expect earnings of −$0.31 per share for FY2026, +8.8% from a year earlier. For FY2027 the average estimate is −$0.31 per share. Anixa Biosciences beat the EPS estimate in 11 of the last 12 quarters.
Related: ANIX income statement, ANIX key metrics, ANIX chart. See the ANIX stock overview for the latest quote and news.
ANIX forecast FAQ
What is Anixa Biosciences's price target?
The average analyst price target for Anixa Biosciences is $9.75, 265.2% above the latest close of $2.67.
Is Anixa Biosciences a buy, hold or sell?
Of 4 analysts covering Anixa Biosciences, 3 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Anixa Biosciences's EPS forecast?
Analysts forecast −$0.31 per share for FY2026 (range −$0.31 to −$0.31); for FY2027 the estimate is −$0.31.
Does Anixa Biosciences usually beat earnings estimates?
Anixa Biosciences reported EPS at or above the analyst estimate in 11 of the last 12 quarters.